Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 48Neoplasms 43Depression 31Fatigue 30Prostatic Neoplasms 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 20Lymphoma, Follicular 18Lymphoma, Large B-Cell, Diffuse 17Multiple Myeloma 16Carcinoma, Non-Small-Cell Lung 16Lymphoma, Non-Hodgkin 15Lung Neoplasms 15Leukemia, Lymphocytic, Chronic, B-Cell 15Lymphoma, Mantle-Cell 14Leukemia, Myeloid, Acute 14Hodgkin Disease 14Colorectal Neoplasms 14Burkitt Lymphoma 14Anxiety Disorders 14Pain 13Lymphoma, B-Cell, Marginal Zone 13Lymphoma, Large-Cell, Immunoblastic 12Lymphoma 11Leukemia, Myeloid, Chronic-Phase 11Head and Neck Neoplasms 11Blast Crisis 11Lymphoma, T-Cell, Cutaneous 10Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 10Leukemia, Myeloid, Accelerated Phase 10Leukemia, Hairy Cell 10

Interventions

pembrolizumab 7Radiotherapy 3Proton Therapy 3Interleukin-2 3Cyclophosphamide 3spartalizumab 2fludarabine 2Rosuvastatin Calcium 2Paclitaxel 2Ipilimumab 2Immune Checkpoint Inhibitors 2Cetuximab 2Carboplatin 2Blood Specimen Collection 2toripalimab 1tislelizumab 1sotorasib 1peposertib 1pazopanib 1patritumab deruxtecan 1palbociclib 1osimertinib 1niraparib 1neotil 1necitumumab 1mirdametinib 1leronlimab 1lenvatinib 1atezolizumab 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor, Adult × Therapeutics × Clear all
NCT04020185 2024-12-11

Safety and Efficacy Study of IMSA101 in Refractory Malignancies

ImmuneSensor Therapeutics Inc.

Phase 1/2 Completed
40 enrolled 16 charts
Other solid neoplasm

Solid Tumor, Adult

Data powered by HemOnc (CC BY 4.0) Colophon âš¡